Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study

This article was originally published here

Results suggest that Entresto, an essential treatment for HFrEF, not only positively impacts a biomarker shown to be associated with prognosis of clinical outcomes in HFrEF, but also

The post Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply